EFMC-ISMC Virtual Event 2020 - Day 2
16:00
Opening Address by EFMC-ISMC Chairman
Prof. Karl-Heinz ALTMANN
ETH ZÜRICH, Zürich, Switzerland
16:10
Session Chair
Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
16:15
Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH
Dr Naoyoshi NOGUCHI
SCOHIA PHARMA, INC., Fujisawa, Japan
Dr. Naoyoshi Noguchi is currently a Principal Scientist in Drug Discovery Chemistry Laboratory at SCOHIA PHARMA, Inc., in Japan, which was established as a carve-out biotech company from Takeda Pharmaceutical Co., Ltd. In 2009, he obtained his Ph.D. in chemistry under the direction of Prof. Masahisa Nakada at Waseda University. During 2009-2017, he had worked in Takeda Pharmaceutical Co., Ltd. as a medicinal chemist. During this period, he was assigned to Tri-Institutional Therapeutics Discovery Institute in New York and took the lead in the cancer metabolism project with Prof. Lewis C. Cantley. In 2017, he joined SCOHIA PHARMA, Inc. and has been engaged in medicinal chemistry research in several target classes mainly for the treatment of cardiovascular, metabolic, and renal diseases.
16:45
The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations
Dr Wooseok HAN
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Songpa-gu, Korea, South
Dr. Wooseok Han is currently a principal scientist in the Global Discovery Chemistry group at Novartis Institutes for BioMedical Research (NIBR) in Cambridge, Massachusetts. In 2005, Dr. Han joined Chiron, which was immediately acquired by Novartis. Since then, he has continued his professional career as a medicinal chemist in the fields of oncology and infectious diseases at NIBR in Emeryville, California. After moving to the Cambridge site in 2018, he has been working on cancer research. Dr. Han received his B.S. in chemistry from Yonsei University and completed her M.S. in organic chemistry from Korea Institute of Science and Technology (KAIST) in South Korea. In 2003, Dr. Han obtained his Ph.D. in organic chemistry at the University of Toronto and joined the Dale Boger group as a post-doctoral research fellow in The Scripps Research Institute, where he studied the total synthesis of complestatin for 2 years.
17:15
GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH)
Dr Fredrik ZETTERBERG
GALECTO BIOTECH, Gothenburg, Sweden
Fredrik Zetterberg is since 6 years Director of medicinal Chemistry at Galecto Biotech, a small biotech company focused on the development of galectin inhibitors for treatment of fibrosis, inflammation and cancer. He obtained his Master of science degree from Gothenburg University 1994, PhD from Uppsala University 1998 working with Pr. David Tanner and Pr. Pher G. Andersson and then moved on to work for AstraZeneca. There he contributed in different roles to several clinical candidates in the cardiovascular and metabolic field. He also discovered Cleviprex ® (clevidipine) during a university project work in collaboration with Astra. In addition he is co-supervisor of PhD students, advisory board member for a Master program in Medicinal chemistry and regular guest lecturer at Lund University. He is author and inventor on >70 publications, patents, posters and oral presentations at international conferences.
17:45
First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases
Dr Riccardo GIOVANNINI
BOEHRINGER INGELHEIM, Biberach, Germany
Since 2015 Riccardo Giovannini is Director Medicinal Chemistry at Boehringer Ingelheim, Biberach, Germany. He received his Ph.D. in 1998 at the University of Camerino (Italy). At the end of 1998 he started his career in the pharmaceutical industry by joining the medicinal chemistry department at GlaxoWellcome Italia. In 2005 he joined Boehringer Ingelheim Italia as Group Leader at the Chemistry Research Centre and two years later he was appointed Department Head. In 2010 he took the responsibility as Managing Director of Boehringer Ingelheim Research Italia, a company focused on pre-clinical research; he kept this responsibility until 2014. His research has prevalently been devoted to the areas of neuroscience and inflammation, contributing as research project leader to the identification of several clinical candidates. Riccardo is co-author/co-inventor of over 70 publications, patents, posters and oral presentations.
18:15
Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other
Dr Uwe GRETHER
F. HOFFMANN-LA ROCHE, Basel, Switzerland
Dr Uwe M. Grether, Senior Principal Scientist, Medicinal Chemistry, F. Hoffmann-La Roche, Ltd. Basel, Switzerland. Uwe received his Ph.D. in chemistry under the direction of Prof. Herbert Waldmann from the University of Karlsruhe in 2000. From 2000-2001 he carried out postdoctoral work in the laboratory of Prof. James D. White at the Oregon State University, Corvallis, OR. In 2001, Uwe joined the Medicinal Chemistry section of F. Hoffmann-La Roche, Ltd. Basel, Switzerland as a research chemist. Over the years he has contributed to a number of drug discovery programs for the treatment of metabolic, cardiovascular, kidney, neuroscience and more recently ophthalmic diseases. Uwe worked as team member and project leader covering both early and late stage research and reaching advanced stages up to phase 3 clinical trials. He is co-author of more than 120 patent applications and research publications.
18:45
Closing Remarks, EFMC-ISMC 2021 and EFMC Events
Prof. Karl-Heinz ALTMANN
ETH ZÜRICH, Zürich, Switzerland
Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
19:00
End of the EFMC-ISMC Virtual Event 2020